Basics Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company. IPO Date: May 1, 2000 Sector: Healthcare Industry: Biotech Market Cap: $12.02B Activated in VL: True Average Daily Range Avg Daily Range: $0.25 | 2.20% Avg Daily Range (30 D): $0.84 | 1.86% Avg Daily Range (90 D): $0.68 | 1.66% Institutional Daily Volume Avg Daily Volume: 2.05M Avg Daily Volume (30 D): 2.27M Avg Daily Volume (90 D): 2.38M Trade Size Avg Trade Size (Sh.): 161 Avg Trade Size (Sh.) (30 D): 62 Avg Trade Size (Sh.) (90 D): 65 Institutional Trades Total Inst.Trades: 11,739 Avg Inst. Trade: $2.85M Avg Inst. Trade (30 D): $6.39M Avg Inst. Trade (90 D): $5.29M Avg Inst. Trade Volume: .16M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $6.58M Avg Closing Trade (30 D): $27.07M Avg Closing Trade (90 D): $21.32M Avg Closing Volume: 325.3K     News Jul 20, 2025 @ 10:30 AM Here's Why This $50 Healthcare Stock Could Be the ... Source: Prosper Junior Bakiny Jul 19, 2025 @ 10:09 AM After Falling 68%, Where Will This Weight-Loss Dru... Source: James Brumley Jul 8, 2025 @ 2:25 PM Amid NCI Budget Fears, Emerging Oncology Stocks Ga... Source: Prnewswire May 18, 2025 @ 8:06 PM CoreWeave, Super Micro Computer And Coinbase Are A... Source: Lekha Gupta May 14, 2025 @ 6:43 PM Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yield... Source: Piero Cingari Financials   TTM Q1 2026 FY 2024 Basic EPS $.57 $1.8 Diluted EPS $.55 $1.76 Revenue $ $ 555.45M $ 2.17B Gross Profit $ $ 536.28M $ 2.09B Net Income / Loss $ $ 159.62M $ 521.27M Operating Income / Loss $ $ 186.86M $ 604.62M Cost of Revenue $ $ 19.17M $ 76.22M Net Cash Flow $ $ -33.62M $ -45.62M PE Ratio